Breaking News

Financial Report: Gilead Sciences

April 23, 2014

Revenues up 97% driven by Sovaldi sales

Gilead Sciences
 
1Q Revenues: $5.0 billion (+97%)

1Q Earnings: $2.2 billion (+210%)

Comments: Antiviral product sales were up 119% to $4.5 billion, driven by Hepatitis C drug Sovaldi, which launched in December 2013 and had $2.3 billion in sales. Stribild sales were up 134% to $215.3 million and Complera/Eviplera sales were up 69% to $250.7 million.Cardiovascular product sales increased to $234.5 million, up 9% primarily driven by Ranexa sales.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision